CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
CCTG will be holding the next CRA Lunch and Learn on Wednesday March 26th, 2025, at 12 pm ET. Session 4 will cover the topic of Introduction to RIPPLE: CCTG's rostering and participants list system
This pivotal study is a move away from current ‘one size fits all’ treatment approaches through the testing of a vulvar cancer patients’ tissue to determine the best treatment options. Researchers want to evaluate if the molecular features in tissues removed in the first surgery can direct the need for additional surgery versus a close follow-up for patients with vulvar squamous cell cancer.
CCTG is heartbroken to share the news that, following a long and courageous battle, Suzanne Wood the GI patient representative has passed away. She died at hospital in Toronto with family by her side at the age of 48 on February 9, 2025.
The CCTG SC30 (RATIONAL) trial has been successfully funded through the CIHR fall competition for nearly $1.2 million over four years. The study will investigate treatment options for patients with blood cancers and low antibody levels to determine the best supportive care interventions to prevent serious infections.
The European Society for Medical Oncology (ESMO) has announced that the recipient of the 2025 TAT Honorary Award is Philippe Bedard, Professor of Medicine at the University of Toronto, Staff Medical Oncologist in the Division of Medical Oncology, Director of the Cancer Genomics Program, and a Principal Investigator in the Bras Drug Development Program at the Princess
